Nyxoah (NASDAQ:NYXH) Releases Earnings Results, Misses Expectations By $0.20 EPS

Nyxoah (NASDAQ:NYXH) issued its earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.20), Zacks reports. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 218.59%. The company had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million.

Nyxoah Stock Down 7.1%

NASDAQ:NYXH traded down $0.10 during mid-day trading on Thursday, hitting $1.31. 168,758 shares of the company’s stock were exchanged, compared to its average volume of 148,589. The company has a market cap of $50.78 million, a PE ratio of -0.52 and a beta of 1.62. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.99 and a quick ratio of 0.88. Nyxoah has a one year low of $1.26 and a one year high of $8.59. The business has a fifty day moving average price of $1.69 and a 200 day moving average price of $2.96.

Hedge Funds Weigh In On Nyxoah

Several institutional investors and hedge funds have recently modified their holdings of NYXH. Raymond James Financial Inc. bought a new position in shares of Nyxoah in the second quarter worth approximately $70,000. Bank of America Corp DE lifted its position in Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after acquiring an additional 3,303 shares in the last quarter. Shay Capital LLC purchased a new stake in Nyxoah during the 2nd quarter valued at $374,000. Citadel Advisors LLC purchased a new stake in shares of Nyxoah during the 3rd quarter valued at about $98,000. Finally, Deutsche Bank AG raised its holdings in shares of Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stifel Nicolaus dropped their target price on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, June 17th. Weiss Ratings downgraded Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 price target (down from $7.00) on shares of Nyxoah in a research report on Thursday. Wall Street Zen upgraded Nyxoah to a “hold” rating in a report on Saturday, August 1st. Finally, Oppenheimer set a $4.00 price objective on Nyxoah in a research report on Thursday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.26.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.